Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) has received a consensus rating of “Buy” from the nine ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $196.75.
Several equities research analysts recently weighed in on KRYS shares. Stifel Nicolaus increased their target price on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Evercore ISI increased their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a report on Monday, August 12th. Citigroup restated a “neutral” rating and set a $204.00 target price (up from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. Finally, HC Wainwright upped their price target on Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th.
Get Our Latest Stock Report on KRYS
Insider Transactions at Krystal Biotech
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Krystal Biotech by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after purchasing an additional 35,632 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Krystal Biotech by 54.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock valued at $117,189,000 after purchasing an additional 231,255 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Krystal Biotech by 1.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock valued at $106,593,000 after purchasing an additional 7,537 shares during the last quarter. Hood River Capital Management LLC boosted its stake in Krystal Biotech by 5.1% during the 2nd quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock valued at $95,694,000 after purchasing an additional 25,507 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Krystal Biotech by 23.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 228,053 shares of the company’s stock valued at $28,292,000 after purchasing an additional 43,709 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.
Krystal Biotech Trading Up 1.3 %
KRYS opened at $174.98 on Friday. The stock has a 50-day moving average price of $185.63 and a 200-day moving average price of $179.97. Krystal Biotech has a 12-month low of $93.95 and a 12-month high of $219.34. The stock has a market capitalization of $5.00 billion, a P/E ratio of 93.57 and a beta of 0.82.
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last issued its earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.03. The company had revenue of $70.28 million during the quarter, compared to analysts’ expectations of $65.27 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. Krystal Biotech’s quarterly revenue was up 70283900.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.25) EPS. On average, equities research analysts predict that Krystal Biotech will post 3.13 EPS for the current year.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Featured Articles
- Five stocks we like better than Krystal Biotech
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Trading Halts Explained
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- How to Calculate Options Profits
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.